Cha Jung-Joon, Yum Yunjin, Kim Yong Hyun, Kim Eung Ju, Rah Yoon Chan, Park Euyhyun, Im Gi Jung, Song Jae-Jun, Chae Sung-Won, Choi June, Joo Hyung Joon
Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.
Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea.
Front Neurol. 2024 Aug 27;15:1410389. doi: 10.3389/fneur.2024.1410389. eCollection 2024.
Hearing loss, affecting a significant portion of the global population, is prevented with peroxisome proliferator-activated receptor γ agonism. Understanding potential protective treatments is crucial for public health. We examine the effect of telmisartan, an antihypertensive drug and partial peroxisome proliferator-activated receptor γ agonist, on hearing loss in patients with hypertension.
This retrospective cohort analysis used data from the OMOP Common Data Model database, encompassing information from three tertiary institutions in South Korea. The study included a substantial sample size of 860,103 people diagnosed with hypertension. The study included individuals who had been medically diagnosed with hypertension and had been prescribed antihypertensive drugs, including telmisartan. The study design was established to evaluate the comparative effects of telmisartan and other hypertension medications on hearing loss. We used propensity score matching (PSM) to create a balanced cohort, reducing potential biases between the telmisartan and non-telmisartan groups. From the initial 860,103 patients with hypertension, a propensity score matched cohort was derived from 20,010 patients, with 2,193 in the telmisartan group. After PSM, lower incidence of total hearing loss was observed in the telmisartan group compared to the non-telmisartan group during the 3-year follow-up (0.5% vs. 1.5%, log-rank = 0.005). In subgroup analysis, this study showed consistent results that lower incidence of total hearing loss was higher in the telmisartan group than in the non-telmisartan group.
Telmisartan was associated with reducing certain types of hearing loss in patients with hypertension. Further research is needed to confirm these findings and understand the mechanisms.
全球相当一部分人口受听力损失影响，而过氧化物酶体增殖物激活受体γ激动作用可预防听力损失。了解潜在的保护性治疗方法对公共卫生至关重要。我们研究了抗高血压药物替米沙坦（一种部分过氧化物酶体增殖物激活受体γ激动剂）对高血压患者听力损失的影响。
这项回顾性队列分析使用了来自OMOP通用数据模型数据库的数据，该数据库包含韩国三所三级医疗机构的信息。该研究纳入了大量样本，共860103名被诊断为高血压的患者。研究对象包括经医学诊断患有高血压并已开具抗高血压药物（包括替米沙坦）的个体。该研究设计旨在评估替米沙坦与其他高血压药物对听力损失的比较效果。我们使用倾向评分匹配（PSM）来创建一个平衡队列，减少替米沙坦组和非替米沙坦组之间的潜在偏差。从最初的860103名高血压患者中，从20010名患者中得出一个倾向评分匹配队列，替米沙坦组有2193名患者。PSM后，在3年随访期间，替米沙坦组的总听力损失发生率低于非替米沙坦组（0.5%对1.5%，对数秩检验 = 0.005）。在亚组分析中，本研究显示了一致的结果，即替米沙坦组的总听力损失发生率低于非替米沙坦组。
替米沙坦与降低高血压患者的某些类型听力损失有关。需要进一步研究来证实这些发现并了解其机制。
